Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2025 value amounting to $59000.0.

  • Orchestra BioMed Holdings' Amortization of Deferred Charges changed N/A to $59000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $154000.0, marking a year-over-year change of. This contributed to the annual value of $31000.0 for FY2024, which is 7232.14% down from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Amortization of Deferred Charges of $59000.0 as of Q3 2025.
  • Orchestra BioMed Holdings' 5-year Amortization of Deferred Charges high stood at $59000.0 for Q3 2025, and its period low was $3000.0 during Q4 2023.
  • Over the past 3 years, Orchestra BioMed Holdings' median Amortization of Deferred Charges value was $36000.0 (recorded in 2022), while the average stood at $38727.3.
  • Data for Orchestra BioMed Holdings' Amortization of Deferred Charges shows a peak YoY increase of 277.78% (in 2023) and a maximum YoY decrease of 9166.67% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Orchestra BioMed Holdings' Amortization of Deferred Charges stood at $36000.0 in 2022, then tumbled by 91.67% to $3000.0 in 2023, then skyrocketed by 1866.67% to $59000.0 in 2025.
  • Its last three reported values are $59000.0 in Q3 2025, $46000.0 for Q2 2025, and $46000.0 during Q1 2025.